News & Events

New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity Recruitment…

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed 75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear…

By Cormac Sheridan, Staff Writer – Published by BioWorld™ – The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a…

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late…